Key Takeaways CRMD acquired Melinta for $300M, adding seven marketed products to its commercial portfolio.CRMD saw$12.8M in Q3 2025 revenues from Melinta products as it diversifies beyond DefenCath.CorMedix eyes near-term growth from Rezzayo, with a $2B-plus antifungal prophylaxis market.CorMedix (CRMD) took a major step to diversify its revenue base and lessen reliance on its lead marketed product, DefenCath (Taurolidine + Heparin), by acquiring Melinta Therapeutics for$300 million in August 2025. The de ...